^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Nectin-4-targeted peptide-drug conjugate

    Related drugs:
    7d
    Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=73, Active, not recruiting, BicycleTx Limited | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • NECTIN4 (Nectin Cell Adhesion Molecule 4)
    |
    zelenectide pevedotin (BT8009)
    7d
    Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) (clinicaltrials.gov)
    P2/3, N=956, Active, not recruiting, BicycleTx Limited | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • gemcitabine • Bavencio (avelumab) • zelenectide pevedotin (BT8009)
    10d
    Duravelo-3: Study of Zelenectide Pevedotin in Participants With Advanced Breast Cancer (clinicaltrials.gov)
    P2, N=66, Active, not recruiting, BicycleTx Limited | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    HER-2 (Human epidermal growth factor receptor 2) • NECTIN4 (Nectin Cell Adhesion Molecule 4)
    |
    HER-2 negative
    |
    zelenectide pevedotin (BT8009)
    24d
    BT8009-202: Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer (2025-521115-40-00)
    P1/2, N=28, Active, not recruiting, Bicycletx Limited | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • NECTIN4 (Nectin Cell Adhesion Molecule 4)
    |
    zelenectide pevedotin (BT8009)
    2ms
    BT8009-202: Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer (2025-521115-40-00)
    P1/2, N=28, Recruiting, Bicycletx Limited
    New P1/2 trial
    |
    BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • NECTIN4 (Nectin Cell Adhesion Molecule 4)
    |
    zelenectide pevedotin (BT8009)
    3ms
    From Cloudy to Clear: A Strategy to Resolve the Complex Structural Elucidation of Bicycle Drug Conjugate Zelenectide Pevedotin by NMR. (PubMed, Bioconjug Chem)
    Its structure is highly complex and comprises a Bicycle connected to microtubule inhibitor monomethyl aurostatin-E (MMAE) via a molecular spacer and a cleavable linker. This provides a unique challenge in structural elucidation, and this report shows a strategy to overcome this using an incremental, nuclear magnetic resonance spectroscopy-based approach, which may be applied to complex structures of a similar nature.
    Journal
    |
    NECTIN4 (Nectin Cell Adhesion Molecule 4)
    |
    zelenectide pevedotin (BT8009)
    5ms
    Duravelo-1: Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies (clinicaltrials.gov)
    P1/2, N=329, Active, not recruiting, BicycleTx Limited | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • ALK (Anaplastic lymphoma kinase) • PGR (Progesterone receptor) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NECTIN4 (Nectin Cell Adhesion Molecule 4)
    |
    EGFR mutation • ALK fusion
    |
    Keytruda (pembrolizumab) • zelenectide pevedotin (BT8009)
    6ms
    First-in-Human, Phase I/II Dose Escalation and Expansion Study of Zelenectide Pevedotin in Patients With Advanced Solid Tumors: Results From Monotherapy Dose Escalation. (PubMed, J Clin Oncol)
    Zelenectide pevedotin monotherapy demonstrated a generally well-tolerated safety profile and preliminary efficacy, particularly in UC, supporting investigation of UC and non-UC populations in the expansion phase.
    P1/2 data • Journal • First-in-human
    |
    NECTIN4 (Nectin Cell Adhesion Molecule 4)
    |
    zelenectide pevedotin (BT8009)
    6ms
    "Precision on Two Wheels"─Structural Refinement of 64Cu- and 68Ga-Labeled Bicyclic Peptides Targeting Nectin-4 for Improved Tumor Imaging: From Preclinical Development to First-in-Human Application. (PubMed, J Med Chem)
    For this purpose, we developed 64Cu- and 68Ga-labeled ligands derived from bicyclic peptide-drug conjugate BT8009...The suitability of the most promising ligand from the preclinical studies, NECT-224, for PET imaging purposes was also demonstrated in a first-in-human application using [68Ga]Ga-NECT-224. The results suggest its further clinical development, but also that of [64Cu]Cu-NECT-224.
    P1 data • Preclinical • Journal • First-in-human
    |
    NECTIN4 (Nectin Cell Adhesion Molecule 4)
    |
    zelenectide pevedotin (BT8009)
    7ms
    Duravelo-1: Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies (clinicaltrials.gov)
    P1/2, N=329, Recruiting, BicycleTx Limited | Trial primary completion date: Dec 2026 --> Mar 2026
    Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • ALK (Anaplastic lymphoma kinase) • PGR (Progesterone receptor) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NECTIN4 (Nectin Cell Adhesion Molecule 4)
    |
    EGFR mutation • ALK fusion
    |
    Keytruda (pembrolizumab) • zelenectide pevedotin (BT8009)
    9ms
    Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=73, Recruiting, BicycleTx Limited | Not yet recruiting --> Recruiting
    Enrollment open
    |
    zelenectide pevedotin (BT8009)
    9ms
    SC-101 in Subjects With Advanced NECTIN4-Amplified Cancers (clinicaltrials.gov)
    P2, N=120, Not yet recruiting, Tianjin ConjuStar Biologics Co., Ltd.
    New P2 trial